MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

Phase 4
Completed
Conditions
Coronary Artery Bypass
Antiplatelet Agents
Interventions
First Posted Date
2014-07-28
Last Posted Date
2019-08-13
Lead Sponsor
Ruijin Hospital
Target Recruit Count
500
Registration Number
NCT02201771
Locations
🇨🇳

Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

🇨🇳

Nan Jing First Hospital, Nanjing, Jiangsu, China

🇨🇳

Henan Provincial People's Hospital, Zhengzhou, Henan, China

and more 3 locations

Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-11
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT02187562

Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.

Phase 3
Terminated
Conditions
Pre-Eclampsia
Interventions
First Posted Date
2014-06-25
Last Posted Date
2019-04-26
Lead Sponsor
Instituto de Investigacion Sanitaria La Fe
Target Recruit Count
81
Registration Number
NCT02174328
Locations
🇪🇸

Obstetrics Unit of La Fe University and Politechnic Hospital, Valencia, Spain

Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules

Phase 2
Completed
Conditions
Multiple Pulmonary Nodules
Current Smoker
Tobacco Use Disorder
Former Smoker
Interventions
Drug: Aspirin
Other: Laboratory Biomarker Analysis
Other: Placebo
First Posted Date
2014-06-23
Last Posted Date
2020-05-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
109
Registration Number
NCT02169271
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇮🇹

European Institute of Oncology, Milano, Italy

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Phase 4
Active, not recruiting
Conditions
Atrial Fibrillation
Stroke
Interventions
First Posted Date
2014-06-20
Last Posted Date
2024-07-17
Lead Sponsor
Ottawa Heart Institute Research Corporation
Target Recruit Count
1284
Registration Number
NCT02168829
Locations
🇩🇪

Segeberger Liniken, Bad Segeberg, Schleswig-Holstein, Germany

🇩🇪

UKSH Lubeck, Lubeck, Schleswig-Holstein, Germany

🇦🇺

Heart Rhythm Clinic, Nedlands, Western Australia, Australia

and more 52 locations

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

First Posted Date
2014-06-17
Last Posted Date
2018-07-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2725
Registration Number
NCT02164864
Locations
🇫🇷

CLI du Pont de Chaume, Montauban, France

🇨🇿

Hospital Jihlava, Jihlava, Czechia

🇩🇪

Klinikum Coburg gGmbH, Coburg, Germany

and more 415 locations

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk

Phase 3
Completed
Conditions
Type 2 Diabetic Patients
Interventions
First Posted Date
2014-06-16
Last Posted Date
2023-11-07
Lead Sponsor
GWT-TUD GmbH
Target Recruit Count
179
Registration Number
NCT02164578
Locations
🇩🇪

GWT-TUD GmbH / Studienzentrum Hanefeld, Dresden, Germany

🇩🇪

Krankenhaus Dresden-Friedrichstadt, Dresden, Sachsen, Germany

🇩🇪

Gemeinschaftspraxis Dr. Schaper/ Dr. Faulmann, Dresden, Germany

and more 2 locations

Low Dose Aspirin for Venous Leg Ulcers

Phase 3
Completed
Conditions
Venous Leg Ulcer
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2014-06-09
Last Posted Date
2019-01-04
Lead Sponsor
University of Auckland, New Zealand
Target Recruit Count
251
Registration Number
NCT02158806

Modulation of Immune Activation by Aspirin

Phase 2
Completed
Conditions
HIV-1 Infection
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2014-06-04
Last Posted Date
2017-06-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
121
Registration Number
NCT02155985
Locations
🇺🇸

Greensboro CRS (3203), Greensboro, North Carolina, United States

🇺🇸

2701 Northwestern University CRS, Chicago, Illinois, United States

🇺🇸

Massachusetts General Hospital ACTG CRS (101), Boston, Massachusetts, United States

and more 12 locations

Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action

Phase 3
Conditions
Colorectal Cancer
Interventions
Drug: Acetylsalicylic acid
Procedure: Screening colonoscopy
First Posted Date
2014-04-29
Last Posted Date
2014-05-05
Lead Sponsor
Aragon Institute of Health Sciences
Target Recruit Count
40
Registration Number
NCT02125409
Locations
🇪🇸

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath